Online inquiry

IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2757MR)

This product GTTS-WQ2757MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF11 gene. The antibody can be applied in Multiple myeloma (MM), Osteoporosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003701.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8600
UniProt ID O14788
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2757MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7040MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ13375MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ6258MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CR-6261
GTTS-WQ12329MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ11374MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ3394MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AT-005
GTTS-WQ3270MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ11256MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI4736
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW